KKKenneth Paul Kirkbride

Kenneth Paul Kirkbride

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kenneth Paul Kirkbride has a total of 258 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Identification of N -debenzisothiazole-lurasidone as an enzymatic degradation product of lurasidone

    by Kyle Farrell, Tristan Fraser, Danielle Butzbach, Jared Castle, Kenneth Paul Kirkbride

    Herein we report the confirmation of N-debenzisothiazole-lurasidone as a lurasidone degradation product associated with postmortem toxicology casework. Confirmation was realized by unambiguous synthesis and comparison of its LC–MS/MS properties to the lurasidone degradation product in postmortem blood using liquid chromatography quadrupole-time-of-flight mass spectrometry (LC–QTOF/MS). The mechanism of formation of this degradant in blood is proposed to be primarily enzymatic, given it has only been previously presumptively reported in one in vitro stability study following oxidative stress conditions. It has not been reported in other in vivo pharmacokinetic and in vitro stability studies assessing lurasidone stability toward acid, alkali, oxidation, photolysis, and heat. The detection of N-debenzisothiazole-lurasidone in postmortem casework indicates that, where possible, it should be included in toxicology screening methods targeting psychoactive compounds. Until such time that a commercially available reference standard of N-debenzisothiazole-lurasidone is available, the comprehensive accurate mass and mass spectral data of N-debenzisothiazole-lurasidone that are now available enable its inclusion as a “suspect target” in high-resolution MS screening methods.

  • Impurity Profiling of ATS Synthesized From Ring‐Substituted APAAN and MAPA Analogs

    by Deanna Langone, Ben Painter, Clark Nash, Janneke W. Hulshof, Sander Oldenhof, Martin R. Johnston, K. Paul Kirkbride

    Designer precursors for the synthesis of amphetamine‐type stimulants pose a significant challenge to law enforcement. The precursors APAAN (α‐phenylacetoacetonitrile) and MAPA (methyl α‐acetylphenylacetate) became popular in the previous decade and have since been restricted. Recently, a ring‐substituted analog of MAPA used for the synthesis of MDMA (3,4‐methylenedioxymethamphetamine) was detected, highlighting the potential for criminal misuse of substituted analogs of these designer precursors. Previous research has characterized the impurity profiles of methamphetamine synthesized from APAAN and MAPA. In this study, the impurity profiles of MDMA and PMMA ( p ‐methoxymethamphetamine) synthesized from ring‐substituted analogs of APAAN and MAPA were characterized. In addition, byproducts forming from the conversion of p ‐methyl and p ‐fluoro analogs of APAAN and MAPA into analogs of P2P were investigated. MDMA was synthesized from 3,4‐methylenedioxy‐substituted MAPA (methyl α‐acetyl‐[3,4‐methylenedioxyphenyl]acetate, MAMDPA) via sodium cyanoborohydride reductive amination and hydrogenation with platinum oxide and methylamine. Four impurities originating from MAMDPA were detected in MDMA synthesized via reductive amination, all of which are 3,4‐methylenedioxy analogs of the impurities detected in methamphetamine synthesized from MAPA. Synthesis of MDMA via the hydrogenation route only produced one characteristic impurity, which, due to its instability under acidic conditions, is not likely to be present in clandestine MDMA hydrochloride samples. PMMA was synthesized via sodium cyanoborohydride reductive amination of MeO‐P2P produced from methoxyl‐substituted APAAN (α‐ p‐ methoxyphenylacetoacetonitrile, APMPAAN). Five impurities were identified as originating from APMPAAN, two of which are proposed to be the most reliable markers for the use of APMPAAN in the synthesis of PMMA.


  • Open Access

    Microbial degradation products of lurasidone and their significance in postmortem toxicology

    by Jared W. Castle, Danielle M. Butzbach, G. Stewart Walker, Claire E. Lenehan, Frank Reith, Samuel P. Costello, K. Paul Kirkbride

    Recent research reported that lurasidone degrades in unpreserved ante-mortem human whole blood inoculated with microorganisms known to dominate postmortem blood specimens. In vitro degradation occurred at a similar rate to risperidone, known to degrade in authentic postmortem specimens until below analytical detection limits. To identify the lurasidone degradation products formed, an Agilent 6520 liquid chromatograph quadrupole-time-of-flight mass spectrometer (LC-QTOF-MS) operating in auto-MS/MS mode was used. Numerous degradation products not previously reported in prior in vitro or in vivo pharmacokinetic studies or forced degradation studies were detected. Accurate mass data, mass fragmentation data, acetylation experiments, and a proposed mechanism of degradation analogous to risperidone supports initial identification of the major degradation product as N-debenzisothiazole-lurasidone (calculated m/z [M + H](+) = 360.2646). A standard was unavailable to conclusively confirm this identification. Retrospective data analysis of postmortem cases involving lurasidone identified the presence of the major degradation product in four of six cases where lurasidone was also detected. This finding is significant for toxicology laboratories screening for this drug in postmortem casework. The major postmortem lurasidone degradation product has consequently been added to the LC-QTOF-MS drug screen at Forensic Science SA (FSSA) to indicate postmortem lurasidone degradation in authentic postmortem blood specimens and as a marker of lurasidone administration in the event lurasidone is degraded to concentrations below detection limits.


  • In vitro degradation of ziprasidone in human whole blood

    by Jared W. Castle, Danielle M. Butzbach, G. Stewart Walker, Claire E. Lenehan, Frank Reith, Samuel P. Costello, K. Paul Kirkbride

    A systematic study was performed into the degradation of ziprasidone in simulated postmortem blood. Fifteen potential degradation products not previously reported in the literature were observed. Four resulted from degradation in human blood, whereas the remaining products resulted from reaction with solvents: four from alkaline degradation, four from reaction with acetaldehyde, and three from reaction with acetone. To identify possible degradation products, a liquid chromatograph-diode array detector (LC-DAD) and liquid chromatograph quadrupole-time-of-flight mass spectrometer (LC-QTOF-MS) operating in auto-MS/MS mode were used. It was indicated from red-shifted UV-Vis spectra, accurate mass data, mass fragmentation data, and a deuteration experiment that the site of ziprasidone degradation, in the in vitro blood experiments, was the methylene carbon of the oxindole moiety. The major in vitro blood degradation products were proposed to be E/Z isomers of 3-ethylidene-ziprasidone. Further, another in vitro degradation product in microbially inoculated blood specimens was proposed to be 3-ethyl-ziprasidone. 3-Ethylidene-ziprasidone was hypothesized to form from the reaction of ziprasidone with acetaldehyde derived from the ethanol used to spike ziprasidone into the in vitro blood experiments. Data from two postmortem investigations were available for retrospective reanalysis. Attempts were made to detect degradation products of ziprasidone, but none were found.

  • Monitoring cell loss through repetitive deposition

    by Piyamas Petcharoen, Kenneth Paul Kirkbride, Adrian Linacre

    Touch DNA deposited on items can be visualised by using fluorescent nucleic acid staining dyes. It might be expected that if a person contacts items multiple times, then at each contact fewer cells should be transferred and deposited. Here we report on the use of Diamond Dye (DD) to monitor any reduction in cellular deposition during multiple contacts. A volunteer, who was assigned as a heavy shedder, was asked to deposit a thumbprint using both left and right thumbs for 15 s onto separate clean glass slides. Thumbprints were collected in triplicate with each mark made for 15 s. Immediately after deposition, a second and then third mark was made in the same way. The three consecutive depositions were repeated 30 times to create 90 tested thumbprints. The number of cells within each entire thumbprint was scored using a cell‐counting program, developed in‐house. The number of cells deposited by the second and third depositions showed a decrease in the cell number compared to the first deposition, by ~70% and ~85% respectively. There was no difference between the percentage of cell persistence from whole thumbprints (16 frames) compared to only scoring part of thumbprints (4 frames). The data obtained provide insight into how cells are deposited by touch and how many cells remain on the thumb for subsequent contact events. Such information may account for cell deposition when performing actions (e.g. loading a firearm or repetitively opening a closing zip‐lock bag).


  • Investigations into the stability of 17 psychoactive drugs in a “simulated postmortem blood” model

    by Jared W. Castle, Danielle M. Butzbach, Frank Reith, G. Stewart Walker, Claire E. Lenehan, Samuel P. Costello, K. Paul Kirkbride

    In the postmortem environment some drugs and metabolites may degrade due to microbial activity, even forming degradation products that are not produced in humans. Consequently, under- or over-estimation of perimortem drug concentrations or even false negatives are possible when analyzing postmortem specimens. Therefore, understanding whether medications may be susceptible to microbial degradation is critical in order to ensure that reliable detection and quantitation of drugs and their degradation products is achieved in toxicology screening methods. In this study, a “simulated postmortem blood” model constructed of antemortem human whole blood inoculated with a broad population of human fecal microorganisms was used to investigate the stability of 17 antidepressant and antipsychotic drugs. Microbial communities present in the experiments were determined to be relevant to postmortem blood microorganisms by 16S rRNA sequencing analyses. After 7 days of exposure to the community at 37 °C, drug stability was evaluated using liquid chromatography coupled with diode array detection (LC-DAD) and with quadrupole time of flight mass spectrometry (LC-QTOF-MS). Most of the investigated drugs were found to be stable in inoculated samples and non-inoculated controls. However, the 1,2-benzisothiazole antipsychotics, ziprasidone and lurasidone, were found to degrade at a rate comparable to the known labile control, risperidone. In longer experiments (seven to twelve months), where specimens were stored at -20 °C, 4 °C, and ambient temperature, N-dealkylation degradation products were detected for many of the drugs, with greater formation in specimens stored at -20 °C than at 4 °C.